Ontario Institute for Cancer Research   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Toronto Canada (2005)

Organization Overview

First Clinical Trial
2014
NCT02017678
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

OICR | Ontario Institute for Cancer Research

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Head and Neck Neoplasms (Phase 2)

Infections (Phase 3)

Mucositis (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 22